Dr Adeola Olaitan, Consultant Gynaecologist & Gynaecological Oncologist
Personal treatment philosophy:
"My main focus is to improve the quality of life of patients with gynaecological malignancies even when a cure is not possible. I work within a multidisciplinary team of experts who, in addition to my surgical expertise, provide world class non-surgical oncological treatment, psychological and social support."
Medical Qualifications
Dr Adeola Olaitan qualified at University College London Hospital in 1987 before going on to be awarded a Medical Doctorate from the same university. She undertook further training in general obstetrics and gynaecology followed by a sub-specialty Fellowship in Gynaecological Oncology at St Michael’s Hospital, Bristol. Dr Olaitan is a Fellow of the Royal College of Obstetricians and Gynaecologists.
Medical Experience
Dr Olaitan was appointed a Consultant at the University College London Hospital (UCLH) in 2002 and is currently clinical lead of the Gynaecological Cancer Centre. She sees patients privately at The Harley Street Clinic, London and at The Portland Hospital, London as a gynaecological oncologist and as a general gynaecologist.
She is a member of the British Gynaecological Cancer Society and the International Gynaecological Cancer Society. Dr Olaitan is also Medical Expert for Eve Appeal Cancer Charity and Jo's Trust Cervical Cancer Charity as well as being the Media Spokesperson for NHS Cervical Screening Programme for which she has appeared on BBC London News, Radio 4 Woman's Hour, ITV, Cosmopolitan magazine and Top Sante magazine. She is presently an Honorary Senior Lecturer at the University College London Hospital and has written over 30 peer-reviewed publications and book chapters.
Dr Olaitan is accredited in colposcopy of the cervix for patients with abnormal smear results and has a particular interest in patients with cervical cancer, endometrial (womb) cancer, ovarian cancer and vulval cancer. She is a specialist in minimally invasive surgery and in maintaining quality of life in patients following cancer treatment.